The U.S. Federal Circuit affirmed the validity of three patents protecting Exelixis’ Cabometyx (cabozantinib), securing exclusivity that the company expects to block generic competition for at least three more years. MSN Pharmaceuticals challenged the patents, arguing invalidity due to an insufficient written description. Exelixis said the precedential ruling strengthens the company’s intellectual property position for Cabometyx while it prepares for longer-term lifecycle protection strategies against generic entry. Patent disputes remain central to oncology market share and pricing durability, especially for blockbuster kinase inhibitors. The outcome reduces near-term uncertainty for Exelixis’ strategy and provides a clearer window for continued commercialization and potential line-extension work.